Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

BACKGROUND: In a parallel-group, international, phase 3 study (ClinicalTrials.govNCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). METHODS: Adults, previously primed with mRNA (BNT162b2, mRNA-127...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruyn, Guy, Wang, Joyce, Purvis, Annie, Ruiz, Martin Sanchez, Adhikarla, Haritha, Alvi, Saad, Bonaparte, Matthew I., Brune, Daniel, Bueso, Agustin, Canter, Richard M., Ceregido, Maria Angeles, Deshmukh, Sachin, Diemert, David, Finn, Adam, Forrat, Remi, Fu, Bo, Gallais, Julie, Griffin, Paul, Grillet, Marie-Helene, Haney, Owen, Henderson, Jeffrey A., Koutsoukos, Marguerite, Launay, Odile, Torres, Federico Martinon, Masotti, Roger, Michael, Nelson L., Park, Juliana, Rivera-Medina, Doris Maribel, Romanyak, Natalya, Rook, Chris, Schuerman, Lode, Sher, Lawrence D., Tavares-Da-Silva, Fernanda, Whittington, Ashley, Chicz, Roman M., Gurunathan, Sanjay, Savarino, Stephen, Sridhar, Saranya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391925/
https://www.ncbi.nlm.nih.gov/pubmed/37533419
http://dx.doi.org/10.1016/j.eclinm.2023.102109

Ejemplares similares

Ejemplares similares